Results 21 to 30 of about 5,217,497 (361)

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

New England Journal of Medicine, 2018
BACKGROUND Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment with surgery and platinum‐based chemotherapy.
K. Moore, N. Colombo, G. Scambia, Byoung-Gie Kim, A. Oaknin, M. Friedlander, A. Lisyanskaya, A. Floquet, A. Leary, G. Sonke, C. Gourley, Susana Banerjee, A. Oza, A. González-Martín, C. Aghajanian, W. Bradley, C. Mathews, Joyce F. Liu, E. Lowe, R. Bloomfield, P. DiSilvestro   +20 more
semanticscholar   +1 more source

Treatment of epithelial ovarian cancer

British medical journal, 2020
Ovarian cancer is the third most common gynecologic malignancy worldwide but accounts for the highest mortality rate among these cancers. A stepwise approach to assessment, diagnosis, and treatment is vital to appropriate management of this disease ...
L. Kuroki, S. Guntupalli
semanticscholar   +1 more source

Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification

npj Precision Oncology, 2021
Endometrioid ovarian carcinoma (EnOC) is an under-investigated ovarian cancer type. Recent studies have described disease subtypes defined by genomics and hormone receptor expression patterns; here, we determine the relationship between these subtyping ...
Robert L. Hollis, Barbara Stanley, John P. Thomson, Michael Churchman, Ian Croy, Tzyvia Rye, Clare Bartos, Fiona Nussey, Melanie Mackean, Alison M. Meynert, Colin A. Semple, Charlie Gourley, C. Simon Herrington   +12 more
doaj   +1 more source

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

New England Journal of Medicine, 2019
BACKGROUND Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP), has been associated with significantly increased progression-free survival among patients with recurrent ovarian cancer after platinum-based chemotherapy ...
A. González-Martín, B. Pothuri, I. Vergote, R. dePont Christensen, W. Graybill, M. Mirza, C. Mccormick, D. Lorusso, P. Hoskins, G. Freyer, K. Baumann, K. Jardon, A. Redondo, R. Moore, C. Vulsteke, R. O'Cearbhaill, B. Lund, F. Backes, P. Barretina-Ginesta, Ashley F Haggerty, M. J. Rubio-Pérez, M. Shahin, G. Mangili, W. Bradley, I. Bruchim, K. Sun, I. Malinowska, Yong Li, D. Gupta, B. Monk   +29 more
semanticscholar   +1 more source

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

New England Journal of Medicine, 2019
BACKGROUND Olaparib has shown significant clinical benefit as maintenance therapy in women with newly diagnosed advanced ovarian cancer with a BRCA mutation.
I. Ray-Coquard, P. Pautier, S. Pignata, D. Pérol, A. González-Martín, R. Berger, K. Fujiwara, I. Vergote, N. Colombo, J. Mäenpää, F. Selle, J. Sehouli, D. Lorusso, E. G. Guerra Alía, A. Reinthaller, S. Nagao, C. Lefeuvre-Plesse, U. Canzler, G. Scambia, A. Lortholary, F. Marmé, P. Combe, N. de Gregorio, M. Rodrigues, P. Buderath, C. Dubot, A. Burges, B. You, E. Pujade-Lauraine, P. Harter   +29 more
semanticscholar   +1 more source

Inhibition of EGFR-AKT axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model [PDF]

, 2012
Ovarian cancer is the leading cause of cancer related deaths in women. Genetic alterations including overexpression of EGFR play a crucial role in ovarian carcinogenesis.
Joseph Alan Bauer, Parul Gupta, Prabodh K. Kandala, Sanjay K. Srivastava, Sivakumar Loganathan   +4 more
core   +3 more sources

EOCSA: Predicting Prognosis of Epithelial Ovarian Cancer with Whole Slide Histopathological Images [PDF]

, 2022
Ovarian cancer is one of the most serious cancers that threaten women around the world. Epithelial ovarian cancer (EOC), as the most commonly seen subtype of ovarian cancer, has rather high mortality rate and poor prognosis among various gynecological cancers. Survival analysis outcome is able to provide treatment advices to doctors.
arxiv   +1 more source

CA125 and Ovarian Cancer: A Comprehensive Review

Cancers, 2020
Simple Summary CA125 has been the most promising biomarker for screening ovarian cancer; however, it still does not have an acceptable accuracy in population-based screening for ovarian cancer.
Parsa Charkhchi, C. Cybulski, J. Gronwald, F. Wong, S. Narod, M. Akbari   +5 more
semanticscholar   +1 more source

DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance

Neoplasia: An International Journal for Oncology Research, 2011
Clinical resistance to chemotherapy is a frequent event in cancer treatment and is closely linked to poor outcome. High-grade serous (HGS) ovarian cancer is characterized by p53 mutation and high levels of genomic instability. Treatment includes platinum-
Euan A. Stronach, Michelle Chen, Elaina N. Maginn, Roshan Agarwal, Gordon B. Mills, Harpreet Wasan, Hani Gabra   +6 more
doaj   +1 more source

Ovarian cancer symptom awareness and anticipated delayed presentation in a population sample [PDF]

, 2014
Background: While ovarian cancer is recognised as having identifiable early symptoms, understanding of the key determinants of symptom awareness and early presentation is limited.
A Bandura, AAPOR, AE Simon, AE Simon, AE Simon, AJ Ramirez, Alice E Simon, BA Goff, BA Goff, C Bankhead, C Maringe, CC Burgess, Ceri White, Chris Roberts, E Grunfeld, EL Low, EM Smith, Iain J Robbé, IM Rosenstock, J Evans, J Hippisley-Cox, J Wardle, Jane Hanson, JL Hay, John Steward, K Robb, Kate E Brain, L Rizzo, Lindsay J Forbes, LJL Forbes, LK Smith, MA Richards, MA Richards, MH Becker, MP Coleman, MR Andersen, MR Andersen, MR Andersen, MR Andersen, National Institute for Health and Clinical Excellence (NICE) guidance, P Sheeran, PM Gollwitzer, RD Neal, Richard D Neal, RS Andersen, S Quaife, S Stubbings, S Tyndel, SE Scott, Stephanie Smits, U Macleod, U Menon, W Hamilton, XD Brouha   +53 more
core   +2 more sources